CN109646561A - A.C.C. extract with anti-inflammatory and antibacterial effect and the composition comprising it as effective component - Google Patents
A.C.C. extract with anti-inflammatory and antibacterial effect and the composition comprising it as effective component Download PDFInfo
- Publication number
- CN109646561A CN109646561A CN201811072025.7A CN201811072025A CN109646561A CN 109646561 A CN109646561 A CN 109646561A CN 201811072025 A CN201811072025 A CN 201811072025A CN 109646561 A CN109646561 A CN 109646561A
- Authority
- CN
- China
- Prior art keywords
- extract
- weight percent
- inflammatory
- interleukin
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/50—Fumariaceae (Fumitory family), e.g. bleeding heart
- A61K36/505—Corydalis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention is provided by Cortex Phellodendri (Phellodendron bark), radix scutellariae (Scutellaria baicalensis), Chinese herbaceous peony (Paeonia lactiflora Pall), shaggy-fruited dittany (Dictamnus dasycarpus Turcz), rhizoma anemarrhenae (Anemarrhena asphodeloides), alum (Alumen), kapur (Dryobalanops aromatica Gaertner), cornmint (Mentha arvensis var.Piperascens), elecampane (Inula helenium), Korea's open country fourth A.C.C. extract and the composition comprising it as effective component made of fragrant (Syringa velutina var.Kamibayashii), C. incisa (Corydalis incisa), Eclipta prostrata (Eclipta prostrata), honeysuckle (Lonicera japonica) and the cooperation of Radix Glycyrrhizae (Glycyrrhiza uralensis) Chinese medicine.A.C.C. extract of the invention, which is presented, reduces tumor necrosis factor-alpha (tumor necrosis factor- α, TNF-α), interleukin-1 ' beta ' (interleukin-1 β, IL-1 β) and interleukin-6 (IL-6) generation, the anti-inflammatory effect for adjusting the expression of iNOS NO is inhibited to generate, it is a kind of substance for clinically alleviating the symptoms such as diaper rash and prickly heat also by anti-inflammatory and antibacterial action, can be used as effective inflammation treatment agent.
Description
Technical field
The present invention relates to extracts and antibacterial and anti-inflammatory composition with anti-inflammatory and antibacterial effect.
Background technique
Restore impaired portion when inflammatory reaction caused by vivo is physics, the chemical stimulation by scar or bacterium infection etc
One of the important body defenses mechanism of position, when being stimulated, vaso-active substance local ionization, thus blood vessel permeability increases
Add, induces inflammation.Also, inflammatory reaction is the recovery system formed in vivo according to outside stimulus, clinically along with
Breaking-out, fever, swelling, pain etc. and occur.The relevant cell of inflammatory reaction has macrophage, single glomus cell, lymph corpuscle, hypertrophy
Cell, fiber sprout cell, blood platelet etc., macrophage (machr ophage) are referred to as causing the main cell of inflammatory reaction,
These are activated the case where being stimulated or by the cell factor (cytokine) of immunocyte secretion, generate nitric oxide
(nitric oxide) (NO) and cytokine, play an important role to biophylaxis.Also, when inflammatory reaction, generates and release
Put the inflammation of histamine, thrombocytin, arachidonic acid (arachidonic acid) metabolism group, active oxygen, cell factor or the like
Disease mediating factors.
Inflammatory reaction repeatedly causes the excessive generation of reactive oxygen species and active nitrogen cluster in inflammatory cell, causes permanent
Thus transgenosis can also result in irreversible lesion.Although that is, inflammatory reaction be in vivo caused by defense mechanism,
When persistently causing inflammatory reaction, promotes mucosa injury, finally cause edema, pain, breaking-out, fever etc., can lead to cardiovascular disease
The disease relevant to chronic inflammation of disease, rheumatoid arthritis, bronchitis and cancer etc.
Taking it by and large, the iNOS and inflammatory reaction phase in nitricoxide synthase (nitric oxide synthase, NOS)
It closes, is expressed because of the stimulation of gamma interferon (interferon- γ), inflammatory cytokine and LPS.It is well known that intracorporal
NO takes on critical function in antibacterial and tumor resection, but causes increase, the edema etc. of blood vessel permeability by the NO that iNOS is formed
Reaction, promotes the synthesis of inflammation mediator, makes increased inflammation.
It is well known that lipopolysaccharides (Lipopolysaccharide, LPS) is the endogenous toxic material in the epicyte of gram-negative bacteria
Element, this stimulating expression of macrophage or single glomus cell, stimulate tumor necrosis factor-alpha (tumor necrosis factor- α, TNF-
α), the inflammatory mediators cell such as interleukin-1 ' beta ' (interleukin-1 β, IL-1 β) and interleukin-6 (IL-6) because
The secretion of sub (cytokine), Lai Cuihua inflammatory reaction.TNF-α is that middle macrophage, lymph corpuscle and leucocyte etc. are raw in vivo
At cell factor (cytokine), do not generate in normal state, if macrophage is stimulated, is synthesized and secretes.
IL-6 is the one kind of representative pro-inflammatory cytokine (pro-inflammatory cytokine), from including single glomus cell
Various kinds of cell in secrete, in the early stage immune response in play an important role.It is well known that IL-1 β is together with IL-6 and TNF-α
It indicates one of representative inflammatory cytokine, is the medium substance of generation NO, and be to cause local inflammation, and realize T
The cytokine of the maturation and NK cell of cell-stimulating and B cell activation.It is reported that the synthesis of this inflammatory mediator substance
With by Cycloxygenase (cyclooxygenase, COX), arachidonic acid (arachidonic acid) is converted into leukotriene
(leukotriene), the process and nitric of prostaglandin (prostaglandin), thromboxane (thromboxane) etc.
The generation of oxide (NO) is related, finally brings mortality result to host.Especially, NO is substance with high reactivity, and is
The substance of effect needed for executing innate immune response to the pathogen of bacterium, virus, bacterium and helminth etc, passes through NO
Synthase (NOS) is made by L-arginine (L-arginine), NOS point for primary type (constitutive NOS,
CNOS it) and induces type (inducible NOS, iNOS).It is known that iNOS is when by outside stimulus or pro-
When the stimulation of inflammatory cytokine etc., a large amount of NO is produced, causes blood vessel permeability and edema etc., induces inflammation
It reacts, under serious situation, also spreads to the immunity disease of rheumatoid arthritis and autoimmune disease etc.With this phase
Guan Di needs to develop the Nature inorganic bone object with antibacterial and anti-inflammatory activity and effective anti-inflammatory therapy agent together.
Summary of the invention
The present invention, which provides, utilizes natural goods Chinese medicine, and the extract with antibacterial and antiphlogistic effects, especially, purpose exists
In confirming that the anti-inflammatory of A.C.C. extract for carrying out distillation extraction to total 14 kinds of Chinese medicine comprising Cortex Phellodendri and obtaining is living
Property, and confirm clinical effectiveness.
Another object of the present invention is to confirmation A.C.C. extract is that there is anti-inflammatory effect and potent antibacterial to imitate together
The effective component of fruit.
Also, it is intended that confirmation A.C.C. extract is clinically also slow by anti-inflammatory and antibacterial action
The substance for solving the symptom of diaper rash and prickly heat etc., thereby confirms that A.C.C. extract can be used as effectively treating diseases associated with inflammation
Agent.
The present invention to solve the above-mentioned problems, is provided by Cortex Phellodendri (Phellodendron bark), radix scutellariae
(Scutellaria baicalensis), Chinese herbaceous peony (Paeonia lactiflora Pall), shaggy-fruited dittany (Dictamnus
Dasycarpus Turcz), rhizoma anemarrhenae (Anemarrhena asphodeloides), alum (Alumen), kapur
(Dryobalanops aromatica Gaermer), cornmint (Mentha arvensis var.Piperascens), soil
Radix aucklandiae (Inula helenium), Korea open country cloves (Syringa velutina var.Kamibayashii), C. incisa
(Corydalis incisa), Eclipta prostrata (Eclipta pro strata), honeysuckle (Lonicera japonica) and Radix Glycyrrhizae
A.C.C. extract made of the cooperation of (Glycyrrhiza uralensis) Chinese medicine.
Especially, which is characterized in that the formula for being used to prepare the Chinese medicine of said extracted object is respectively Cortex Phellodendri
(Phellodendron bark) 16~24 weight percent, 1~7 weight hundred of radix scutellariae (Scutellaria baicalensis)
Divide ratio, Chinese herbaceous peony (Paeonia lactiflora Pall) 5~11 weight percent, shaggy-fruited dittany (Dictamnus dasycarpus
Turcz) 5~11 weight percent, rhizoma anemarrhenae (Anemarrhena asphodeloides) 1~7 weight percent, alum
(Alumen) 4~12 weight percent, kapur (Dryobalanops aromatica Gaertner) 1~7 weight percent
Than, cornmint (Mentha arvensis var.Piperascens) 1~7 weight percent, elecampane (Inula
Helenium) 1~7 weight percent, Korea open country cloves (Syringa velutina var.Kamibayashii) 1~7 weight
Percentage, C. incisa (Corydalis incisa) 1~7 weight percent, Eclipta prostrata (Eclipta prostrata) 1~7 weight
Amount percentage, honeysuckle (Lonicera japonica) 1~7 weight percent, Radix Glycyrrhizae (Glycyrrhiza uralensis) 1~
7 weight percent.
Said extracted object, which is characterized in that total 14 kinds of Chinese medicine comprising Phellodendron bark (Cortex Phellodendri)
The sample (A.C.C. extract) for carrying out distillation extraction and obtaining has antibacterial and anti-inflammatory activity.In related experiment, confirmation
The nitric oxide of cell is discharged in 264.7 cell of RAW stimulated by lipopolysaccharides (Lipopolysaccharide, LPS)
(NO) production quantity and inflammatory cells tumor necrosis factor-alpha (tumor necrosis factor- α, TNF-α), leucocyte are situated between
The variation of -1 β of element (interleukin-1 β, IL-1 β) and interleukin-6 (IL-6) production quantity.As a result, A.C.C is extracted
Object no cytotoxicity it is potent inhibition by the generation of LPS increased NO and inflammatory cytokine.
And, which is characterized in that A.C.C. extract of the invention is to Pseudomonas aeruginosa (Pseud omonas
Aeruginosa), staphylococcus aureus (Staphylococcus aureus), methicillin-resistant staphylococcus aureus
(MRSA, Methicillin-resistant Staphylococcus aureus), candida albicans (Candida albicans)
And variation hammer (Streptococcus mutans) bacterium has antibacterial action.A.C.C. extract is presented in above-mentioned bacterium
99.9% potent bacterial reduction, it means that A.C.C. extract is having with anti-inflammatory effect and antibacterial effect together
Imitate ingredient.
In related experiment, Pseudomonas aeruginosa (Pseudomonas aeruginosa), staphylococcus aureus are utilized
(Staphylococcus aureus), methicillin-resistant staphylococcus aureus (MRSA, Methicillin-resistant
Staphylococcus aureus), candida albicans (Candida albicans) and variation hammer (Streptococcus
Mutans) bacterial strain confirms antibacterial activity, its clinic is applicable in, to the infant for suffering from diaper rash, pruritus, prickly heat symptom
When being coated with A.C.C. extract, eruption is presented, allergic skin, festers, the symptoms improvement such as pruritus, prickly heat, meat can be used
The prickly heat of eye confirmation infant's skin is alleviated pretty good after 2 weeks.Thus A.C.C. extract can be confirmed in clinic
Upper is also the substance for alleviating the symptoms such as diaper rash and prickly heat by anti-inflammatory and antibacterial action, and A.C.C. extract can become pair
The effective alternative solution of diseases associated with inflammation.
Another aspect of the present invention, which is characterized in that provide comprising above-mentioned A.C.C. extract as the anti-of effective component
Bacterium and anti-inflammatory composition.Since the synergistic effect of anti-inflammatory effect and antibacterial action is presented in above-mentioned A.C.C. extract,
It can be used as effective inflammation treatment agent.
The A.C.C. extract for carrying out distillation extraction to a total of 14 kinds of Chinese medicine comprising Cortex Phellodendri and obtaining has together
There are anti-inflammatory effect and potent antibacterial effect.
Also, A.C.C. extract of the invention reduces the generation of TNF-α, IL-1 β and IL-6, is thus presented by adjusting
The expression of iNOS and inhibit NO generate anti-inflammatory effect.
Therefore, A.C.C. extract of the invention is clinically also to alleviate diaper rash by anti-inflammatory and antibacterial action
And the substance of the symptoms such as prickly heat, it can be used as effective inflammation treatment agent.
Detailed description of the invention
Fig. 1 is the schematic diagram that the distillation of 14 natural goods comprising phellodendron bark (Cortex Phellodendri) is extracted.
Fig. 2 is to indicate using the confirmation of MTT assay method with LPS processing A.C.C extract and to 264.7 cell band of Raw
The chart of the result for the toxicity come.(*, p < 0.05, * *, p < 0.01compared to control.Con;Control, LPS 1
μg/ml;1 μ g/mllipopolysaccharide, A0;LPS 1 μ g/ml, A1;A.C.C.1 μ g/ml, A5;A.C.C.5 μ g/ml,
A10;10 μM of A.C.C.10 μ g/ml, Q.C;quercetin 10μM.)
Fig. 3 is to indicate to be induced in 264.7 cell of Raw by LPS and increased NO generates concentration due to A.C.C. extract
The chart inhibited to dependence.(###, p < 0.001compared to control, and***, p < 0.001compared to
1μg/ml LPS.Con;1 μ g/ml of control, LPS;1 μ g/ml lipopolysaccharide, A0;LPS 1 μ g/ml, A1;
A.C.C.1 μ g/ml, A5;A.C.C.5 μ g/ml, A10;10 μM of A.C.C.10 μ g/ml, Q.C;quercetin 10μM.)
Fig. 4 is to indicate that A.C.C. extract generates the figure for inhibiting bring effect to the cytokine of 264.7 cell of Raw
Table.
(a) A.C.C. extract is on dose-dependent influence (the Effects of A.C.C.extracts on of TNF-α
TNF-αin dose-dependent manner)。
(b) A.C.C. extract is on dose-dependent influence (the Effects of A.C.C.extracts on of IL-1 β
IL-1β in dose-dependent manner)。
(c) A.C.C. extract is on dose-dependent influence (the Effects of A.C.C.extracts on of IL-6
IL-6in dose-dependent manner)。
Pro-inflammatory cytokines is the Raw264.7 cell stimulated by LPS, is surveyed in the medium
It is fixed.1 μ of ###, p < 0.001compared to control, and**, p < 0.01, and***, p < 0.001compared to
g/ml LPS.Con;1 μ g/ml of control, LPS;1 μ g/ml lipopolysaccharide, A0;LPS 1 μ g/ml, A1;
A.C.C.1 μ g/ml, A5;A.C.C.5 μ g/ml, A10;A.C.C.10μg/ml.
Fig. 5 is the chart for indicating the symptom variation using diaper rash after A.C.C. extract and prickly heat etc..(n=
18) .*, p < 0.05, and***, p < 0.001compared to 0week
Fig. 6 is the picture for indicating the symptom variation using diaper rash after A.C.C. extract and prickly heat etc..
Specific embodiment
Hereinafter, by embodiment, the more detailed description present invention.But these embodiments only example of the invention
The property shown contents, and the scope of the invention is not limited to these embodiments.
1. material of embodiment select and the preparation of A.C.C. extract
Based on Herbal Textuals, file investigation is carried out, picks out 14 kinds of Chinese medicine in total.Chinese medicine has purchased to be enabled by Soul medicine
The product for being packaged as crude drug preparation and selling that the CK (strain) in city produces.Dahl Burke Improved Eagle Medium (Dulbecco '
S modified eagle ' s me dium, DMEM), fetal calf serum (fetal bovine serum, FBS) purchase in Hai Kelong
(Hyclone) (Logan, UT, USA).Penicillin (Penicillin) (100U/mL), streptomysin (streptomycin)
(100ug/ml) purchase in Gibco (life technology Co., Ltd, Gaithersburg, MD, USA, Life technology 1nc.,
Gaithersburg, MD, USA).LPS, 3- (4,5- dimethylthiazole -2- base) -2,5- diphenyltetrazolium bromide bromide (3- (4,5-
Dimethylthiazol-2-y1) -2,5-diphenyl tetrazolium bromide, MTT), sodium nitrite (Sodium
Nitrite), dimethyl sulfoxide (Dimethyl sulfoxide) (DMSO) buys sigma chemistry product company (Sigma
Chemical Co.) (St.Louis, MO, USA).Nitrite oxide (NO) detection kit (detection Kit) purchase
It is used in introne (iNtron), elisa assay kit (assaykit) is bought in Thermo Fischer Scient Inc.
(Thermo Fisher Scientific)。
According to each ratio, cooperate 13 kinds of Chinese medicines other than Cortex Phellodendri, third distilled water 40L is used as solvent,
11 hours (referring to Fig.1, table 1) is extracted in distillation at 80 DEG C.
Table 1
Ratio in 1. material of table and A.C.C. extract
Experimental example 1: the cytotoxicity assay based on MTT assay
The culture of 264.7 cell of Raw
264.7 cell of Raw is bought in Korea Cell strain bank.Using contain Penicillin/stre ptomycin
The DMEM culture medium of 100unit/ml and 10%FBS, the culture in 37 DEG C, 5%CO2 incubator (incubator), every 3 days one
Secondary carry out squamous subculture.
96 orifice plates (well plate) are adjusted to 2 × 10 by the measurement of 264.7 cells survival rate of Raw4Cells/well's
After concentration, cultivates 24 hours, execute stabilisation.After 24 hours, the culture medium of well is all removed.A.C.C. to be extracted
The mode that the ultimate density of object reaches 1,5,10 μ g/ml is diluted in culture solution, and handles after cell strain, cultivates 3 hours.3
After hour, 1 μ g/ml of LPS is handled in the well other than control group.After removing culture medium after 24 hours, each
Well adds MTT solution (0.2 μ g/ml is without phenol red DMEM, 0.2 μ g/ml in phenol red free DMEM) 100 μ l,
37 DEG C, react 2 hours in 5%CO2incubator, restore MTT.Later, it is given birth in each well addition DMSO solution to dissolve
At formazan (formazan).Using microplate reader (Microplate reader), absorbance is measured at 545nm.
The measurement of experimental example 2:Nitric Oxide production quantity
In 6well plate, with 1 × 105The concentration of cells/well adds 264.7 cell of Raw.In 37 DEG C, 5%
After taking care of 24 hours in CO2incubator, 1,5,10 μ g/ml A.C.C. extracts are handled in 264.7 cell of Raw, 3 is small
When after, handle 1 μ g/ml of LPS, cultivate 24 hours.With the nitrite for being based on Griess reaction (Griess reaction)
Oxide (NO) detection kit (iNtron) analyzes nitric oxide.Ge Lisi is put into cell culture supernatant
Reagent (Griess Reagent) simultaneously mixes, and after reacting 10 minutes at normal temperature, utilizes microplate reader (microplate
Reader), measured under 520nm absorbance.Based on the various concentration standard curve of sodium nitrite (Sodium nitrite), fit
For in formula, determining the NO concentration in culture solution.
Experimental example 3: the measurement of inflammation correlation cytokines secretory volume
1 × 10 is added in 6well plate5264.7 cell of Raw of the concentration of cells/well, to measure conduct
TNF-α, IL-6 the and IL-1 β production quantity of inflammation induction cell factor.After 24 hours, 1,5,10 μ g/ml A.C.C. of processing are mentioned
Object is taken, after 3 hours, the LPS of 1 μ g/ml is handled in all well other than control group.After culture 24 hours, benefit
With ELISA kit (Thermo Fisher Scientific), TNF-α of the analysis secretion in culture medium, IL-6 and IL-1 β.Benefit
With Microplate reader, measure at 450 nm.
Experimental example 4: the measurement of antibacterial activity
In order to watch the antibacterial activity of A.C.C. extract, antimicrbial power is measured using paper disc (paper disc).Test it
The test strain of preceding culture, 1.0 × 104It is seeded in each culture medium above.A.C.C.100 μ l is loaded in the paper disk of sterilizing
Later, 30 minutes dry, with spare.On the culture medium of inoculation test bacterial strain, the paper for being mounted with A.C.C. is placed at intervals
After disk, cultivated 24-48 hours in incubator.Measure the periphery Paper disk inhibition zone, carry out result judgement and
Analysis.
Experimental example 5: clinical research
The subject convened by bulletin makes " preparatory questionnaire " by agent (guardian) according to Properties of Objects.
By preparatory questionnaire survey, after grasping symptom, skin condition etc., composition is provided, it is same daily that researcher educates subject
The time of sample is coated with 5-10 times with the amount of daily 1cc, so coating 14 days.Also, for objective result of study, shooting is suffered from
Locate picture, comparative analysis coating before with coating after, at this time in picture except as face can recognize individual position.Coating 14
After it, agent's production " test questionnaire ".According to life ethics method, the time terminated from research is lighted for the keeping organ of data
Keeping 3 years, during information protection after, personal information and picture will pass through irrecoverable method permanent delet.
Experimental example 6: statistical analysis
All measured values are indicated by average ± standard deviation value, examine (t-test) suitably by two sides independent sample t-
Or variance analysis test (ANOVA test) executes statistical analysis.Cell mean between each group shows sizable difference
When, by post method Scheffe ' s method, it is applicable in the analysis.
Experimental result
1.A.C.C. extract is to cytotoxicity caused by 264.7 cell of Raw
In order to confirm A.C.C. extract on influence caused by 264.7 cell of Raw, by various concentration (1,5,10 μ g/m1)
After pre-processing A.C.C. extract, the LPS of 1 μ g/ml is handled.After culture 24 hours, MTT assay method, confirmation are utilized
Cytotoxicity.The confirmation of its result, cells survival rate is respectively 98.47,90.91,93.23%, is not presented to cells survival significant
The high survival rate (Fig. 2) of meaning.
2.A.C.C. extract, which generates the NO of 264.7 cell of Raw, inhibits bring effect
When with macrophage-stimulating LPS, inducible nitric oxide synthase (inducible nitric oxide is expressed
Synthase, iNOS), generate excessive NO.The NO of generation promotes inflammatory reaction, induces tissue damage.Therefore, it to report
A.C.C. whether extract inhibits the inflammatory mediators substance of NO etc.The confirmation of its result handles LPS in 264.7 cell of Raw
When, compared with the control group, NO is generated from 0.45 and is increased to 3.15, that is, increases by 7 times.It is mentioned when with 1,5,10 μ g/ml processing A.C.C.
When taking object and measuring the generation inhibitory effect of NO, result confirmation, in 264.7 cell of Raw due to LPS is induced increased NO
Generation is suppressed to concentration dependent (referring to Fig. 3) due to A.C.C. extract.
3.A.C.C. extract, which generates the cytokine of 264.7 cell of Raw, inhibits bring effect
During inducing inflammatory reaction, along with the generation of the inflammatory mediator object of NO and PGE2 etc and by immune
The generation of the inflammatory cytokine of reaction.Representative cytokine has TNF-α, IL-1 β and IL-6.In order to watch A.C.C.
Which kind of influence extract brings to inflammatory mediator cytokine generation, by ELISAassay method, measures TNF-α, IL-1 β
And the variable quantity of IL-6.By various concentration, after 264.7 cell of Raw handles A.C.C. extract, LPS processing is carried out.Its
As a result, 264.7 cell of Raw handle LPS when, compared with the control group, TNF-α, IL-1 β and IL-6 increase quite a lot of (figure
4).But by handling A.C.C. extract, reduce TNF-α, IL-1 β and IL-6.Especially, it is handled when with 10 μ g/ml concentration
A.C.C. when extract, reduce quite a lot of.Confirmed by this result, A.C.C. extract inhibits in 264.7 cell of Raw
The cytokine of middle induction inflammation, thus has anti-inflammatory effect.
The antibacterial activity effect of 4.A.C.C. extract
As itch, the main pathogenic fungi of children's eruption, it is known that A group streptococcus (Streptococcus pyogenes) and
Staphylococcus aureus (Staphylococcus aureus).Also, as women vaginitis (Vaginal
Candidiasis), eruption, scratchiness main pathogen fungi, have Candida albicans (Candidaalbicans), as a result, when
The skins such as the thigh root of male fold and humidity position by mycotic infection when, jock itch or intertriginous candidiasis etc can occur
Skin infection disease.In this experiment, by the method for following table, to Pseudomonas aeruginosa (Pseudomonas aeruginosa),
Staphylococcus aureus (Staphylococcus aureus), methicillin-resistant staphylococcus aureus (MRSA,
Methicillin-resistantStaphylococcus aureus), candida albicans (Candida albicans) and variation
Hammer (Streptococcus mutans) bacterium is tested, and A.C.C. extract is presented in the bacterial strain for being total up to 5 kinds
99.9% potent bacterial reduction (%) (table 2).
Table 2
The antibacterial activity effect of table 2.A.C.C. extract
Therefore, it is known that A.C.C. extract is the effective component for having potent antibacterial effect to above 5 kinds of bacterium.
Influence of the 5.A.C.C. extract to the diaper rash, prickly heat of infant
Infant with diaper rash, pruritus, prickly heat symptom is faced when being coated with A.C.C. extract as object
Confirmed on bed eruption, allergic skin, fester, whether the symptoms such as pruritus, prickly heat are improved.Before clinical test, to go out
Rash allergic skin, is festered, 5 kinds of projects in total such as pruritus and prickly heat, and preparatory questionnaire survey is carried out.With 4 points in total for full marks
It carries out, eruption project is 2.61 ± 1.1 points, highest, and secondly the high prickly heat project of score is 2.41 ± 1.1 points.Production is asked in advance
After volume, daily in the same time, one day 5~10 times coating 1cc amounts, so coating 14 days, after spending 14 days, production is tested
Questionnaire.As a result, the use of rear score being 1.5 points hereinafter, the form improved on the whole is presented.Use preceding highest eruption
It is all respectively 1.39 ± 0.70,1.35 ± 0.70 points with prickly heat, confirmation reduces to obtain considerable result (Fig. 5, table 3).Also,
To before the clinical test of infant with by A.C.C. extract be coated with 1 week after, and by A.C.C. extract be coated with 2 weeks it
Process afterwards is compared and observes.As a result, can confirm when the prickly heat of skin is passed through 2 weeks and disappear quite a lot of.Therefore,
A.C.C. extract is considered as (referring to Fig. 6) effective to the symptom of diaper rash and prickly heat etc..
Table 3
Table 3.A.C.C. extract influences the diaper rash of infant, prickly heat bring
By above-mentioned experimental result of the invention, A.C.C. extract can be confirmed in the RAW as mouse macrophage
Do not have cytotoxicity (Fig. 2) in 264.7 cells, it means that the effect that A.C.C. extract is presented in cell is and cell
Survival rate the unrelated intrinsic effect of variation.
In order to confirm the anti-inflammatory effect of A.C.C. extract, with various concentration, A.C.C. extract is pre-processed in RAW
264.7 cells 3 hours after handling 1 μ g/ml LPS 24 hours, measure the generation variation of inflammatory factors NO in cell.Its
As a result, according to LPS, increased NO production quantity by A.C.C. extract concentrations dependence reduces (Fig. 3).
This result means that A.C.C. extract inhibits important medium factor NO in the inflammatory process carried out by LPS
Formation, thus have anti-inflammatory effect.
Also, when starting inflammatory reaction, the transcription factor NF-KB of inflammatory reaction is activated, adjust TNF-α, IL-1 β and
The important inflammation of IL-6 etc promotes the gene expression of albumen, it is known that these adjust the activation of iNOS and play weight to inflammatory reaction
It acts on.It is thus identified that inflammatory mediator cell factor (TNF-α, IL-1 β and IL-6) band of the important indicator as inflammation
The effect of the A.C.C. extract come.LPS is handled in 264.7 cell of RAW, induces inflammation, at this point, confirmation A.C.C. extract
How the result of TNF-α, the production quantity of IL-1 β and IL-6 is changed, it is seen that the potent reduction in A.C.C. extract concentrations dependence ground
The inflammatory factor (Fig. 4) induced by LPS.
It is clearly learnt by these results, A.C.C. extract reduces the generation of TNF-α, IL-1 β and IL-6, thus presents
The anti-inflammatory effect that expression by adjusting iNOS inhibits NO to generate.Also, A.C.C. extract is to Pseudomonas
aeruginosa、Staphylococcus aureus、MRSA(Methicillin-resistant Staphylococcus
Aureus), Candida albicans and Streptococcus murans bacterium, are presented 99.9% potent bacterial reduction
(%) (table 1).This illustrates that A.C.C. extract is the effective inflammation that the synergy of anti-inflammatory effect and antibacterial action is presented
Therapeutic agent has utilizability.In order to clearly confirm these, the infant of diaper rash, pruritus, prickly heat symptom will be suffered from
As object, whether have when having rated coating A.C.C. eruption, allergic skin, fester, the symptom of pruritus, prickly heat etc. improves
Effect.Evaluate preparatory questionnaire the results show that eruption project is 2.61 ± 1.1 points, and highest makes in the case where 4 points is full marks
After 14 days, score is 1.39 ± 0.70 points, than reducing quite a lot of before using (Fig. 5).Also, observe facing for infant
The result that bed tests forward and backward process can confirm that when using A.C.C. extract 2 weeks, the prickly heat of skin is alleviated quite not
It is wrong.This is clearly stated, and A.C.C. extract is clinically also to alleviate diaper rash and prickly heat by anti-inflammatory and antibacterial action
Deng symptom substance (Fig. 6).Therefore, there is the A.C.C. extract of anti-inflammatory and antibacterial effect and as main material
Product can be used as to the effective alternative solution of diseases associated with inflammation.
Claims (6)
1. a kind of A.C.C. extract, which is characterized in that by Cortex Phellodendri, radix scutellariae, Chinese herbaceous peony, shaggy-fruited dittany, rhizoma anemarrhenae, alum, kapur, Japan
Peppermint, elecampane, Korea open country cloves, C. incisa, Eclipta prostrata, honeysuckle and traditional Chinese medicine of licorice root material cooperate.
2. A.C.C. extract according to claim 1, which is characterized in that the cooperation of the Chinese medicine is respectively Cortex Phellodendri 16
~24 weight percent, 5~11 weight percent of Chinese herbaceous peony, 5~11 weight percent of shaggy-fruited dittany, are known 1~7 weight percent of radix scutellariae
Female 1~7 weight percent, 4~12 weight percent of alum, 1~7 weight percent of kapur, 1~7 weight hundred of cornmint
Divide ratio, 1~7 weight percent of elecampane, 1~7 weight percent of Korea open country cloves, 1~7 weight percent of C. incisa, murrel
1~7 weight percent of intestines, 1~7 weight percent of honeysuckle, 1~7 weight percent of Radix Glycyrrhizae.
3. A.C.C. extract according to claim 1, which is characterized in that have antibacterial and anti-inflammatory activity.
4. A.C.C. extract according to claim 1, which is characterized in that for Pseudomonas aeruginosa, staphylococcus aureus,
Methicillin-resistant staphylococcus aureus, candida albicans and Streptococcus mutans have antibacterial action.
5. A.C.C. extract according to claim 1, which is characterized in that reduce the tumour as pro-inflammatory cytokine
Necrosis factor-alpha (tumor necrosis factor- α, TNF-α), interleukin-1 ' beta ' (interleukin-1 β, IL-1 β)
And the generation of interleukin-6 (IL-6), there is anti-inflammatory effect.
6. a kind of antibacterial and anti-inflammatory composition, which is characterized in that include A.C.C. described in any one of claims 1 to 5
Extract is as effective component.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170181881A KR102118540B1 (en) | 2017-12-28 | 2017-12-28 | A.C.C. extracts having anti-inflammatory and antimicrobial effects and composition comprising it as an active ingredient |
KR10-2017-0181881 | 2017-12-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109646561A true CN109646561A (en) | 2019-04-19 |
Family
ID=66110232
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880090176.7A Pending CN112805021A (en) | 2017-12-28 | 2018-07-20 | A.C.C. extract having anti-inflammatory and antibacterial effects, and composition containing the same as active ingredient |
CN201811072025.7A Pending CN109646561A (en) | 2017-12-28 | 2018-09-14 | A.C.C. extract with anti-inflammatory and antibacterial effect and the composition comprising it as effective component |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880090176.7A Pending CN112805021A (en) | 2017-12-28 | 2018-07-20 | A.C.C. extract having anti-inflammatory and antibacterial effects, and composition containing the same as active ingredient |
Country Status (5)
Country | Link |
---|---|
US (1) | US11590191B2 (en) |
KR (1) | KR102118540B1 (en) |
CN (2) | CN112805021A (en) |
DE (1) | DE112018006698T5 (en) |
WO (1) | WO2019132147A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102305336B1 (en) * | 2019-12-11 | 2021-09-28 | 주식회사 네오캠코리아 | Natural antibacterial agent and cosmetic composition for improving atopic dermatitis |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000060612A (en) * | 1999-03-18 | 2000-10-16 | 한영복 | Pharmaceutical composition comprising mixed-extract of phellodendron cortex and anemarrhena rhizoma for alalgesic and anti-inflammation |
CN1943664A (en) * | 2005-10-07 | 2007-04-11 | 毛伟平 | The Chinese traditional medicinal cream for treatment of eczema |
KR20100059188A (en) * | 2008-11-26 | 2010-06-04 | 양근영 | Composition for external application to skin and preparation method thereof |
CN102727639A (en) * | 2012-07-03 | 2012-10-17 | 许瑞琴 | External-use medicine for treating venereal disease |
JP2016190822A (en) * | 2015-03-31 | 2016-11-10 | 一丸ファルコス株式会社 | Inflammation transition-inhibiting external composition for skin |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006124356A (en) * | 2004-11-01 | 2006-05-18 | Ichimaru Pharcos Co Ltd | INTERLEUKIN-1alpha PRODUCTION INHIBITOR |
-
2017
- 2017-12-28 KR KR1020170181881A patent/KR102118540B1/en active IP Right Grant
-
2018
- 2018-07-20 DE DE112018006698.3T patent/DE112018006698T5/en active Pending
- 2018-07-20 CN CN201880090176.7A patent/CN112805021A/en active Pending
- 2018-07-20 WO PCT/KR2018/008250 patent/WO2019132147A1/en active Application Filing
- 2018-07-20 US US16/954,670 patent/US11590191B2/en active Active
- 2018-09-14 CN CN201811072025.7A patent/CN109646561A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000060612A (en) * | 1999-03-18 | 2000-10-16 | 한영복 | Pharmaceutical composition comprising mixed-extract of phellodendron cortex and anemarrhena rhizoma for alalgesic and anti-inflammation |
CN1943664A (en) * | 2005-10-07 | 2007-04-11 | 毛伟平 | The Chinese traditional medicinal cream for treatment of eczema |
KR20100059188A (en) * | 2008-11-26 | 2010-06-04 | 양근영 | Composition for external application to skin and preparation method thereof |
CN102727639A (en) * | 2012-07-03 | 2012-10-17 | 许瑞琴 | External-use medicine for treating venereal disease |
JP2016190822A (en) * | 2015-03-31 | 2016-11-10 | 一丸ファルコス株式会社 | Inflammation transition-inhibiting external composition for skin |
Non-Patent Citations (3)
Title |
---|
国家中医药管理局《中华本草》编委会: "《中华本草 3》", 31 December 1999, 上海科学技术出版社 * |
张冠英等: "川黄柏、关黄柏的化学成分及药理活性研究进展", 《沈阳药科大学学报》 * |
杨卫平等: "《新编中草药图谱及经典配方 5》", 31 May 2014, 贵州科技出版社 * |
Also Published As
Publication number | Publication date |
---|---|
US11590191B2 (en) | 2023-02-28 |
CN112805021A (en) | 2021-05-14 |
US20200353028A1 (en) | 2020-11-12 |
DE112018006698T5 (en) | 2020-09-10 |
WO2019132147A1 (en) | 2019-07-04 |
KR20190079849A (en) | 2019-07-08 |
KR102118540B1 (en) | 2020-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sharma et al. | The chemical constituents and diverse pharmacological importance of Tinospora cordifolia | |
Kadiyala et al. | Calotropis gigantiea (L.) R. Br (Apocynaceae): A phytochemical and pharmacological review | |
Hossain et al. | Andrographis paniculata (Burm. f.) Wall. ex Nees: a review of ethnobotany, phytochemistry, and pharmacology | |
Saleh et al. | Genus Parkia: Phytochemical, medicinal uses, and pharmacological properties | |
Yu et al. | Bioactive components in the fruits of Ziziphus jujuba Mill. against the inflammatory irritant action of Euphorbia plants | |
Visuvanathan et al. | Revisiting Trigonella foenum-graecum L.: pharmacology and therapeutic potentialities | |
Ibrar et al. | Quantitative ethnobotanical survey of medicinal flora thriving in Malakand Pass Hills, Khyber Pakhtunkhwa, Pakistan | |
Alshehri et al. | Pharmacological efficacy of Tamarix aphylla: a comprehensive review | |
Zheng et al. | Systematic review of Lonicerae Japonicae Flos: A significant food and traditional Chinese medicine | |
Hossain et al. | Evaluation of morning glory (Jacquemontia tamnifolia (L.) Griseb) leaves for antioxidant, antinociceptive, anticoagulant and cytotoxic activities | |
Choudhari et al. | Evaluating the anti-inflammatory potential of Tectaria cicutaria L. rhizome extract in vitro as well as in vivo | |
Almeleebia et al. | Pharmacological and clinical efficacy of Picrorhiza kurroa and its secondary metabolites: a comprehensive review | |
Chirisa et al. | Evaluation of in vitro anti-inflammatory and antioxidant activity of selected Zimbabwean plant extracts | |
Ibrahim et al. | Phytoconstituents and pharmacological activities of Indian Camphorweed (Pluchea Indica): A multi-potential medicinal plant of nutritional and ethnomedicinal importance | |
Lerma-Herrera et al. | Biological activities of organic extracts of the genus Aristolochia: A review from 2005 to 2021 | |
Wahab et al. | Potential pharmacological applications of nigella seeds with a focus on Nigella sativa and its constituents against chronic inflammatory diseases: Progress and future opportunities | |
Khan et al. | Economic and medicinal properties of some medicinal plants found in Kashmir Himalaya | |
CN109646561A (en) | A.C.C. extract with anti-inflammatory and antibacterial effect and the composition comprising it as effective component | |
Jamuna et al. | Phytochemical and pharmacological properties of certain medicinally important species of Cucurbitaceae family—A review | |
CN104474021A (en) | Traditional Chinese medicine composition for treatment of exterior heat and preparation method thereof | |
Deori et al. | To evaluate the anti-inflammatory activity of ethanolic extract of leaves of Mikania micrantha on experimental animal models | |
Sutar et al. | Lichens: traditional use and biological activities | |
Singab et al. | Herbal arsenal against skin ailments: a review supported by in silico molecular docking studies | |
Akbar et al. | Hyssopus officinalis L.(Lamiaceae) (Syns.: H. altissimus Mill.; H. angustifolius M. Bieb.; H. hirsutus Hill; H. torresii Sennen; H. vulgaris Bubani) | |
CN105663097B (en) | A kind of sesquiterpenoid is preparing the application in inhibiting acute inflammation drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190419 |
|
WD01 | Invention patent application deemed withdrawn after publication |